CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 2.89: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.05BCNY454.30M · vs all stocks (USD)
Revenue (TTM)
625.30MCNY92.99M · vs all stocks (USD)
Profit Margin
-1.85%vs Biotechnology peers
Beta
0.2590xvs all stocks
52-Week Change
-33.86%vs all stocks
Market Capitalization
3.05BCNY454.30M · vs all stocks (USD)
Enterprise Value
2.48BCNY369.38M · vs all stocks (USD)
Forward P/E
9.68xvs Biotechnology peers
Price to Sales (TTM)
4.76xvs Biotechnology peers
Price to Book (MRQ)
1.30xvs Biotechnology peers
Enterprise to Revenue
3.97xvs Biotechnology peers
Enterprise to EBITDA
18.22xvs Biotechnology peers
Gross Margin
76.97%vs Biotechnology peers
Profit Margin
-1.85%vs Biotechnology peers
Operating Margin
18.74%vs Biotechnology peers
Return on Assets (TTM)
1.19%vs Biotechnology peers
Return on Equity (TTM)
-0.50%vs Biotechnology peers
Revenue (TTM)
625.30MCNY92.99M · vs all stocks (USD)
Revenue per Share (TTM)
3.13CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-8.50%vs Biotechnology peers
Gross Profit (TTM)
486.26MCNY72.31M · vs all stocks (USD)
EBITDA (TTM)
137.45MCNY20.44M · vs all stocks (USD)
Net Income (TTM)
-11.56MCNY-1.72M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-50.70%vs Biotechnology peers
Operating Cash Flow (TTM)
188.37MCNY28.01M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-24.59MCNY-3.66M · vs all stocks (USD)
5-Year Average Dividend Yield
1.27%vs all stocks
Payout Ratio
39.13%vs Biotechnology peers
Minority Interest (Equity)
925.86KCNYFY2025 · Dec 31, 2025Revenue
640.18MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
136.55MCNYFY2025 · Dec 31, 2025Gross Profit
503.63MCNYFY2025 · Dec 31, 2025Operating Income
123.90MCNY18.42M · vs all stocks (USD)
Pre-tax Income
102.14MCNYFY2025 · Dec 31, 2025Income Tax Expense
84.02MCNYFY2025 · Dec 31, 2025Net Income
18.12MCNYFY2025 · Dec 31, 2025EBIT
126.35MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
210.76MCNYFY2025 · Dec 31, 2025Research & Development
51.64MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
226.29MCNYFY2025 · Dec 31, 2025Other Operating Expenses
11.08MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
15.38MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
24.21MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0900CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0900CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
201.94MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
201.94MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
18.12MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
54.14KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
15.71MCNYFY2025 · Dec 31, 2025Free Cash Flow
-257.47MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
212.18MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
18.12MCNYFY2025 · Dec 31, 2025Other Non-cash Items
46.02MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-15.02MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-33.42MCNYFY2025 · Dec 31, 2025Capital Expenditures
-273.18MCNYFY2025 · Dec 31, 2025Purchase of Investments
-929.14MCNYFY2025 · Dec 31, 2025Sale of Investments
918.01MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-284.32MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
456.80MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-418.01MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-59.50MCNYFY2025 · Dec 31, 2025Other Financing Charges
-17.62MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-38.33MCNYFY2025 · Dec 31, 2025Shares Outstanding
198.24MSharesUpdated Aug 21, 2026Float Shares
111.94MSharesUpdated Aug 21, 2026% Held by Insiders
46.22%vs all stocks
% Held by Institutions
1.33%vs all stocks
Total Cash (MRQ)
1.06BCNY157.35M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.34CNYUpdated Aug 21, 2026Total Debt (MRQ)
564.45MCNY83.94M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2464xvs Biotechnology peers
Current Ratio (MRQ)
3.13xvs Biotechnology peers
Book Value per Share (MRQ)
11.55CNYUpdated Aug 21, 2026Total Assets
3.28BCNY488.00M · vs all stocks (USD)
Total Current Assets
1.47BCNYFY2025 · Dec 31, 2025Total Liabilities
1.02BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.81BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
475.26MCNYFY2025 · Dec 31, 2025Total Current Liabilities
545.83MCNYFY2025 · Dec 31, 2025Cash
777.39MCNYFY2025 · Dec 31, 2025Cash Equivalents
1.00MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
778.39MCNYFY2025 · Dec 31, 2025Other Short-term Investments
356.16MCNYFY2025 · Dec 31, 2025Accounts Receivable
71.30MCNYFY2025 · Dec 31, 2025Inventory
208.91MCNYFY2025 · Dec 31, 2025Accounts Payable
160.32MCNYFY2025 · Dec 31, 2025Short-term Debt
211.49MCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.34MCNYFY2025 · Dec 31, 2025Long-term Debt
403.49MCNYFY2025 · Dec 31, 2025Common Stock (Book)
198.24MCNYFY2025 · Dec 31, 2025Retained Earnings
1.02BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.26BCNY336.15M · vs all stocks (USD)
52-Week Low
12.62CNYUpdated Aug 21, 202652-Week High
22.97CNYUpdated Aug 21, 202652-Week Change
-33.86%vs all stocks
Beta
0.2590xvs all stocks
50-Day MA
14.64CNYUpdated Aug 21, 2026200-Day MA
18.14CNYUpdated Aug 21, 2026Avg 10-Day Volume
2.20MSharesUpdated Aug 21, 2026Avg 30-Day Volume
2.59MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.0500CNYUpdated Aug 21, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
How is this stock valued?
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
Where is this company structurally exposed?
Down-Close Share With Multi-Year Earnings Decrease
Most weeks closed down this year, and earnings and gross profit fell over four.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.77Profit Margin: -0.02
Financial Health
Altman Z-Score 2.89: safe zoneNotable
Altman Z-Score: 2.89
High earnings qualityNotable
Earnings Quality Score: 0.51
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
ClearPoint Neuro Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Ever Supreme Bio Technology Co., Ltd
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nanjing Medlander Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Prothena Corporation plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Allergy Therapeutics plc
Tier 1ProductionApproval-Gated PipelineRule
Kyverna Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guizhou Yibai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Editas Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guanhao Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cybin Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Liaoning Chengda Biotechnology Co., Ltd.
3 interpretationsDown-Close Share With Multi-Year Earnings DecreasePrice Below Mean With Profitability And EquityIndustry-Benchmarked ROA and Margin Elevated
Galapagos NV
2 interpretationsPrice Below Mean With Profitability And EquityIndustry-Benchmarked ROA and Margin Elevated
Shantou Institute of Ultrasonic Instruments Co., Ltd.
2 interpretationsPrice Below Mean With Profitability And EquityIndustry-Benchmarked ROA and Margin Elevated